cabazitaxel

FDA-approved 2010 Indications: - advanced androgen-insensitive prostate cancer Dosage: - 25 mg/m2 every 3 weeks - up to 10 cycles - given in conjunction with prednisone 10 mg/day Adverse effects: - diarrhea - neutropenia, including febrile neutropenia - increased risk of death within 30 days of last dose Mechanism of action: - binds tubulin

General

taxane antineoplastic agent (chemotherapeutic agent)

References

- de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010 Oct 2; 376:1147. PMID: 20888992